DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL

Phase 2

Not yet recruiting

Conditions: Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
HSCT
Tyrosine Kinase Inhibitor

Interventions: Drug: Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.

First Posted Date: 2024-10-26

Last Posted Date: 2024-10-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 50

Registration Number: NCT06658925

A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP

Phase 2

Recruiting

Conditions: Primary Immune Thrombocytopenia

Interventions: Drug: Dexamethasone monotherapy
Drug: Dexamethasone Combined with romiplostim N01

First Posted Date: 2024-10-26

Last Posted Date: 2024-10-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 129

Registration Number: NCT06658834

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Not Applicable

Not yet recruiting

Conditions: B-ALL

Interventions: Drug: Blinatumomab

First Posted Date: 2024-10-26

Last Posted Date: 2024-10-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 30

Registration Number: NCT06658938

Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia

Not Applicable

Not yet recruiting

Conditions: AML

First Posted Date: 2024-10-16

Last Posted Date: 2024-12-30

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 358

Registration Number: NCT06643195

Locations: 🇨🇳
Hebei Medical University Second Hospital, Shijiazhuang, Hebeisheng, China
🇨🇳
Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China
🇨🇳
The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army, Jinan, Shandong, China

and more 1 locations

Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML

Phase 2

Recruiting

Conditions: AML (Acute Myelogenous Leukemia)

Interventions: Drug: combined chemotherapy

First Posted Date: 2024-10-10

Last Posted Date: 2024-10-10

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 1200

Registration Number: NCT06635681

Locations: 🇨🇳
Blood Diseases Hospital, Tianjin, Tianjin, China

CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia

Phase 1

Not yet recruiting

Conditions: Severe Aplastic Anemia
Relapse
Refractory
CAR T-cell Therapy

Interventions: Biological: RD13-02

First Posted Date: 2024-10-02

Last Posted Date: 2024-10-02

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 15

Registration Number: NCT06622694

Locations: 🇨🇳
Regenerative Medicine Clinic Center, Tianjin, Tianjin, China

Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia

Phase 2

Recruiting

Conditions: Aplastic Anemia
TPO Receptor Agonists

Interventions: Drug: standard IST combined with Romiplostim N01

First Posted Date: 2024-09-26

Last Posted Date: 2024-12-04

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 48

Registration Number: NCT06613880

Locations: 🇨🇳
Regenerative Medicine Center and Red Blood Cell Disorders Center, Tianjin, Tianjin, China

Venetoclax and Ivosidenib Combined With Chemotherapy in IDH1 Mutated AML

Phase 1

Not yet recruiting

Conditions: AML
IDH1 Mutation
Treatment

Interventions: Drug: Ivosidenib,venetoclax,azacytidine,cytarabine

First Posted Date: 2024-09-25

Last Posted Date: 2024-11-05

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 29

Registration Number: NCT06611839

Twice-per-weekSelinexor, 2 Days Melphalan

Phase 3

Not yet recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Selinexor
Drug: Melphalan
Drug: Intravenous Busulfan
Drug: Fludarabine

First Posted Date: 2024-09-25

Last Posted Date: 2024-09-25

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 126

Registration Number: NCT06613035

Locations: 🇨🇳
Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China
🇨🇳
Hebei Medical University Second Hospital, Shijiazhuang, hebeisheng, China
🇨🇳
The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army, Jinan, Shandong, China

and more 1 locations

National Longitudinal Cohort of Hematological Diseases (NICHE) - CART

Recruiting

Conditions: Hematological Malignancies

First Posted Date: 2024-09-23

Last Posted Date: 2024-09-23

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 1000

Registration Number: NCT06607289

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy